- Research article
- Open Access
Adaptive mechanisms of Campylobacter jejunito erythromycin treatment
© Xia et al.; licensee BioMed Central Ltd. 2013
- Received: 18 January 2013
- Accepted: 10 June 2013
- Published: 14 June 2013
Macrolide is the drug of choice to treat human campylobacteriosis, but Campylobacter resistance to this antibiotic is rising. The mechanisms employed by Campylobacter jejuni to adapt to erythromycin treatment remain unknown and are examined in this study. The transcriptomic response of C. jejuni NCTC 11168 to erythromycin (Ery) treatment was determined by competitive microarray hybridizations. Representative genes identified to be differentially expressed were further characterized by constructing mutants and assessing their involvement in antimicrobial susceptibility, oxidative stress tolerance, and chicken colonization.
Following the treatment with an inhibitory dose of Ery, 139 genes were up-regulated and 119 were down-regulated. Many genes associated with flagellar biosynthesis and motility was up-regulated, while many genes involved in tricarboxylic acid cycle, electron transport, and ribonucleotide biosynthesis were down-regulated. Exposure to a sub-inhibitory dose of Ery resulted in differential expression of much fewer genes. Interestingly, two putative drug efflux operons (cj0309c-cj0310c and cj1173-cj1174) were up-regulated. Although mutation of the two operons did not alter the susceptibility of C. jejuni to antimicrobials, it reduced Campylobacter growth under high-level oxygen. Another notable finding is the consistent up-regulation of cj1169c-cj1170c, of which cj1170c encodes a known phosphokinase, an important regulatory protein in C. jejuni. Mutation of the cj1169c-cj1170c rendered C. jejuni less tolerant to atmospheric oxygen and reduced Campylobacter colonization and transmission in chickens.
These findings indicate that Ery treatment elicits a range of changes in C. jejuni transcriptome and affects the expression of genes important for in vitro and in vivo adaptation. Up-regulation of motility and down-regulation of energy metabolism likely facilitate Campylobacter to survive during Ery treatment. These findings provide new insight into Campylobacter adaptive response to antibiotic treatment and may help to understand the mechanisms underlying antibiotic resistance development.
Campylobacter jejuni is a Gram-negative, spiral-shaped, motile bacterium and is a leading cause of bacterial food-borne enteritis in humans [1, 2]. Most human C. jejuni infections are acquired by consuming or handling contaminated poultry, milk or water. Clinical symptoms of campylobacteriosis can range from mild diarrhea to fever, headache, abdominal cramping, vomiting and bloody diarrhea. Studies also demonstrated that Campylobacter infection is associated with Guillain-Barré syndrome as a post-infection complication .
Although most campylobacteriosis cases are self-limiting, antibiotic therapy may be necessary for severe or persistent illness . Macrolide, such as erythromycin (Ery), is the drug of choice for treating campylobacteriosis, but the frequency of resistance to this class of antibiotic is rising [5, 6]. As an inhibitor of protein translation in bacterial cells, Ery and other macrolide antibiotics interfere with aminoacyl translocation, preventing the transfer of the tRNA bound at the A site to the P site of the rRNA complex. Without this translocation, the A site remains occupied and thus precludes the incoming tRNA from attaching its amino acid to the nascent polypeptide [7–9]. The molecular mechanism of resistance to Ery in C. jejuni has been extensively studied and is conferred largely by target modification (such as mutations in the 23S rRNA gene and ribosomal proteins) [6, 7, 10] and antibiotic efflux pumps . Although the genetic basis of Ery resistance in C. jejuni has been well characterized, there is very little knowledge of the initial response and adaptive mechanism of C. jejuni to Ery exposure.
Transcriptomic analysis has been used to assess bacterial adaptive responses to antibiotic treatments. Three previous studies reported global gene expression patterns of Streptococcus pneumonia, Escherichia coli, and Haemophilus influenzae to sub-inhibitory doses of translation-inhibiting antibiotics. These reports demonstrated that exposure to these bacteriostatic antibiotics triggered the synthesis of a number of ribosomal proteins [12–14]. Other studies analyzed the transcriptional profiles of Staphlococcus aureus, E. coli, and Yersinia pestis under inhibitory doses of chloramphenicol, mupirocin, ampicillin, or ofloxacin [15–17], and a common observation of these studies was the repression of energy metabolism genes by these antibiotics. Although the transcriptomic response of C. jejuni to a fluoroquinolone antibiotic has been reported , it remains unknown how this organism responds to macrolide treatment.
In this study, the genome-wide transcriptional response of C. jejuni following exposure to both inhibitory and sub-inhibitory doses of Ery was assessed. Furthermore, contribution of several differentially expressed genes to antibiotic resistance, stress resistance, and host colonization was determined using isogenic gene knock-out mutants.
Transcriptional responses of NCTC 11168 to an inhibitory dose of Ery
COG category of differentially-expressed genes in NCTC 11168 in response to treatment with an inhibitory dose of Ery
No. up-regulated (%)*
No. down-regulated (%)*
Total No. differentially expressed genes
Amino acid transport and metabolism
Carbohydrate transport and metabolism
Cell cycle control, mitosis and meiosis
Cell wall/membrane biogenesis
Coenzyme transport and metabolism
Energy production and conversion
General function prediction only
Intracellular trafficking and secretion
Inorganic ion transport and metabolism
Lipid transport and metabolism
Nucleotide transport and metabolism
Posttranslational modification, chaperones
Replication, recombination and repair
Signal transduction mechanisms
Within the up-regulated genes, several belong to putative transcriptional units (operons) including cj0061c-cj0062c, cj0309c-cj0310c, cj0345-cj0349, cj0423-cj0425, cj0951c-cj0952c, and cj1173-cj1174. cj0061c encodes a flagellar biosynthesis sigma factor and cj0062c encodes a putative integral membrane protein. Each of the cj0309c-cj0310c and cj1173-cj1174 operons encodes a putative multidrug efflux system in C. jejuni. Genes cj0345-cj0349 are predicted to encode subunits of anthranilate synthase and tryptophan synthase. cj0423-cj0425 encode putative integral membrane/periplasmic proteins whose functions remain unknown. cj0951c-cj0952c encode proteins forming a putative chemoreceptor, which was demonstrated to be associated with host cell invasion, motility and chemotaxis towards formic acid .
Many of the down-regulated genes belonged to the “energy production and conversion” category (Table 1). Approximately 31.58% (30 out of 95) of the genes classified in “energy production and conversion” were down-regulated in response to the inhibitory Ery treatment. Included in this category were several putative operons, such as cj0073c-cj0076c, cj0107-cj0108, cj0437-cj0439, cj0531-cj0533, cj0781-cj0783, cj1184c-cj1185c, cj1265c-cj1266c, and cj1566-cj1567. Several ORFs in other COGs also showed a substantial level of down-regulation and these included cj0662c-cj0663c, which encode an ATP-dependent protease ATP-binding subunit HslU and an ATP-dependent protease peptidase subunit; cj1427c-cj1428c, which encode two proteins belonging to carbohydrate transport and metabolism; and cj1598-cj1599, which encode two amino acid transport and metabolism proteins.
Transcriptional responses of NCTC 11168 to a sub-inhibitory dose of Ery
COG category of differentially-expressed genes in NCTC 11168 in response to treatment with a sub-inhibitory dose of Ery
No. up-regulated (%)*
No. down-regulated (%)*
Total No. differentially expressed genes
Amino acid transport and metabolism
Carbohydrate transport and metabolism
Cell wall/membrane biogenesis
Coenzyme transport and metabolism
General function prediction only
Inorganic ion transport and metabolism
Lipid transport and metabolism
Posttranslational modification, chaperones
Replication, recombination and repair
Signal transduction mechanisms
Differentially-expressed genes in NCTC 11168 in response to inhibitory/sub-inhibitory Ery treatments
flagellar biosynthesis sigma factor
putative anthranilate synthase component I
tryptophan synthase subunit beta
flagellar basal body rod protein FlgG
conserved hypothetical protein Cj0916c
putative MCP-domain signal transduction protein
putative HAMP containing membrane protein
branched-chain amino-acid ABC transport system periplasmic binding protein
putative periplasmic protein
50-KDa outer membrane protein precursor
putative periplasmic protein
putative two-component sensor (histidine kinase)
qRT-PCR confirmation of representative differentially expressed genes initially identified by microarray
Transcriptional responses of EryRC. jejuniJL272 to Ery treatment
JL272 is an EryR derivative of NCTC 11168 and was isolated from a chicken fed tylosin-containing feed . This strain bears a A2074G mutation in its 23S rRNA gene, which confers a high-level erythromycin resistance (MIC = 1024 mg/L) . The transcriptional profile of this strain was assessed after treatment with 4 mg/L of Ery, the same concentration used for the inhibitory treatment of the wild-type strain. Interestingly, only a total of three genes were up-regulated, while a single gene was down-regulated. The up-regulated genes were cj0862c, cj1006c and cj1706c, which encode para-aminobenzoate synthase component I, a hypothetical protein and 50S ribosomal subunit protein RplD, respectively. The down-regulated gene, cj0030, encodes a hypothetical protein. The small number of affected genes in the EryR strain suggests that little stress is imposed to JL272 by 4 mg/L of Ery.
Characterization of cj0309c-cj0310c and cj1173-cj1174
Two of the operons up-regulated by Ery treatment were cj0309c-cj0310c and cj1173-cj1174, which encode putative small multidrug resistance (SMR) efflux transporters. However, their functions have not been determined. The SMR family of transporters are characterized by their short length (100–150 amino acids), four trans-membrane α-helical motifs, and the use of the proton motive force to export a broad range of antiseptics and drugs out of the cell . The paired small multidrug resistance (PSMR) protein family is one of the SMR sub-classes, which requires co-expression of two homologues including a typical SMR length protein and a protein with longer hydrophilic loops .
Bacterial strains and plasmids used in this study
Strain or plasmid
Description or relevant genotype
Source or reference
Campylobacter jejuni wild-type strain
NCTC 11168 derivative erythromycin resistant strain
Jun Lin 
NCTC 11168 Δcj1169c-cj1170c::cat mutant
NCTC 11168 Δcj0423-cj0425::aphA3 mutant
NCTC 11168 Δcj0309c-cj0310c::cat mutant
NCTC 11168 Δcj1173-cj1174::aphA3 mutant
NCTC 11168 Δcj0309c-cj0310::cat, Δcj1173-cj1174::aphA3 mutant
KOp50Q complementation strain; Δcj1169c-cj1170c::cat, ITS1::cj1169c-cj1170c complementation strain
DKO01Q complementation strain; Δcj0309c-cj0310::cat, Δcj1173-cj1174::aphA3, ITS1::cj1173-cj1174
Escherichia coli strain for plasmid propagation
Polymerase chain reaction cloning vector, AmpR**
Complementation cloning vector
pRR with aphA3; KanR**
pRR with tetO; TetR**
cj1169c-cj1170c::cat cloned into pUC19
cj0423-cj0425::aphA3 cloned into pUC19
cj0309c-cj0310c::cat cloned into pUC19
cj1173-cj1174::aphA3 cloned into pUC19
cj1169c-cj1170c cloned into pRRK
cj0309c-cj0310c cloned into pRRK
cj1173-cj1174 cloned into pRRT
Characterization of the cj0423-cj0425operon
Primers used in this study
Sequence*(5’ → 3’) (restriction enzyme)
Primers for mutant construction
TTTGCTAGCGGACTA TTATTGTTTGGCTTGT (NheI)
Primers for complementation construction
Primers for qRT-PCR
Primers for conventional RT-PCR
Characterization of cj1169c-cj1170coperon
The microarray and qRT-PCR results demonstrated that cj1169c and cj1170c were up-regulated in both inhibitory and sub-inhibitory treatments with Ery (Tables 3 and 4). cj1169c and cj1170c encode a putative periplasmic protein and a 50 kDa outer membrane protein precursor, respectively . Recently, cj1170c was characterized as an outer-membrane tyrosine kinase, phosphorylating a number of membrane proteins . To identify the role of the two genes in adaptation to Ery treatment, both genes were deleted to produce the mutant strain KOp50Q. The mutation did not affect the transcript abundance of the downstream gene, cj1168c, as determined by qRT-PCR (data not shown). The mutant was complemented to produce strain Comp50Q.
The wild-type and mutant strains demonstrated comparable growth rates in MH broth without or with sub-inhibitory (1/2, 1/4, 1/8, and 1/16× MIC) concentrations of Ery (data not shown). Additionally, no significant difference in motility was observed between the mutant and wild-type strains. Furthermore, the MIC test revealed no significant differences between the wild type strain and KOp50Q in susceptibility to a number of antimicrobials including ampicillin, erythromycin, tylosin, ciprofloxacin, tetracycline, phosphonomycin, cetylpyridinium chloride, chloramphenicol, nalidixic acid, novobiocin, ethidium bromide and crystal violet (results not shown). Likewise, as shown by the disk diffusion assay, no significant differences were revealed between the mutant and wild-type strains in sensitivity to oxidative stress agents including H2O2 and cumene hydroperoxide (data not shown). However, the aerobic stress experiments indicated that the mutant was more susceptible than the wild-type strain to higher levels of oxygen, although they showed comparable growth under microaerobic conditions (Figure 2C). Complementation of the mutant (Comp50Q) partially restored the phenotype to the wild-type level (Figure 2C).
In this study, we determined the transcriptomic changes in C. jejuni in response to Ery treatment in an attempt to identify initial molecular mechanisms involved in adaptation to macrolide challenge and resistance development. Wild-type Ery-susceptible C. jejuni NCTC 11168 was exposed to different doses of Ery to reveal the adaptive responses to inhibitory and sub-inhibitory antibiotic challenges. In addition to NCTC 11168, its EryR derivative JL272 strain was also exposed to Ery at a concentration considered inhibitory for the wild-type (4 mg/L). A relatively short treatment period (30 min) was chosen in order to minimize possible collateral effects that might occur from prolonged drug treatment. Transcriptomic analyses revealed a number of genes with altered expression levels in response to Ery treatment, of which the most obvious changes are up-regulation of genes involved in cell motility and down-regulation of genes involved in energy production (Table 1).
Ery and other macrolide antibiotics block the ribosome elongation tunnel to prevent movement and release of the nascent peptide during bacterial protein synthesis. Previous studies have demonstrated that treatment of E. coli and H. influenza with translation inhibitors (such as puromycin, tetracycline, chloramphenicol, and erythromycin) increased the relative synthesis rate of a number of ribosomal proteins and translation factors as a possible compensating mechanism [12, 14]. Consistent with the findings in other bacteria, treatment of C. jejuni with an inhibitory dose of Ery increased the transcription of ribosomal proteins, translation initiation factor (IF-1) and transcription elongation factor (nusA) (Table 1; Additional file 1). This finding suggests that C. jejuni increases transcription of these genes in order to help recover halted peptide elongation and resume translation as its immediate response against the antibiotic exposure. Interestingly, treatment of an EryR strain (JL272) with a dose of Ery inhibitory for its wild-type ancestor did not trigger noticeable transcriptomic responses. This observation suggests that the 23S RNA mutation in JL272 prevented the interaction of Ery with its target and consequently prohibited the induction of a transcriptomic response in C. jejuni.
Of note, several functional gene categories were significantly affected in the wild-type C. jejuni by an inhibitory dose of Ery (Table 1), suggesting that C. jejuni alters multiple pathways to cope with Ery stress. Most of the differentially expressed genes in the COG category “energy production and conversion” were down-regulated (Table 1), suggesting that reduced energy metabolism occurred as an adaptive response to inhibitory treatment with Ery. This result is consistent with findings in other bacteria such as Staphlococcus aureus, E. coli, and Y. pestis, which demonstrated significant down-regulation of “energy metabolism” genes under treatment with different classes of antibiotics [15–17]. Taken together, these observations suggest that reduced energy metabolism may be a general transcriptional response to antibiotic-induced stress in both Gram-positive and Gram-negative bacteria. Other COG categories with a noticeably high proportion of down-regulated genes (as compared with the proportion of up-regulated genes in the same categories) included “cell wall/membrane biogenesis”, “carbohydrate transport and metabolism”, and “nucleotide transport and metabolism” (Table 1 and Additional file 1). These changes suggest that C. jejuni decreased the general metabolic rates to prolong the survival time under Ery challenge.
Genes involved in “transcription” and “translation” was noticeably up-regulated. In the COG category of “transcription”, up-regulated genes included flagellar biosynthesis sigma factor (fliA), putative transcriptional regulator (cj1563c), transcription elongation factor NusA (nusA) and heat-inducible transcription repressor (hrcA) (Additional file 1). Among the up-regulated genes in the “translation” category included 50S ribosomal protein L1 (rplA), L20 (rplT), 30S ribosomal protein S2 (rpsB), and translation initiation factor IF-1 (infA) (Additional file 1). Since Ery targets 50S ribosomal proteins and block the ribosome elongation tunnel, this finding suggests that C. jejuni increases transcription of these genes in order to help recover the halted peptide elongation and resume translation as its immediate response against the antibiotic exposure. In the “Defense mechanism” category, two genes were up-regulated after inhibitory treatment, which encode putative MATE family transport protein (cj0619) and ABC-type transmembrane transport protein (cj0607). The role of these genes in the adaptation to Ery treatment remains undetermined.
The “cell motility” category comprised the largest proportion of up-regulated genes in response to an inhibitory dose of Ery in wild-type C. jejuni (Table 1), suggesting that enhanced motility might be Campylobacter’s initial escape response to this noxious stress. cj0061c, which encodes the σ28 transcription factor fliA and is essential for normal flagellar biosynthesis , is up-regulated in NCTC 11168 when treated with inhibitory and sub-inhibitory doses of Ery (Table 3). This gene induction was independently confirmed by qRT-PCR (Table 4). Previous research indicated that σ28 regulates the major flagellin gene (flaA) and other late genes of the flagellar regulon as well as some non-flagellar genes in C. jejuni. Also, it has been demonstrated that the flaA promoter can be activated by the intestinal environment and C. jejuni chemotactic effectors, such as bovine bile, deoxycholate, L-fucose, osmolarity, aspartate, glutamate, organic acids citrate, fumarate, α-ketoglutarate and succinate . The microarray and qRT-PCR results presented here revealed that Ery induced expression of this regulatory gene (fliA), which might explain why multiple motility genes were up-regulated in C. jejuni under Ery treatment.
Compared with the inhibitory-dose Ery treatment, sub-inhibitory dose Ery triggered a much smaller response in the overall transcription in C. jejuni (Table 2 and Additional file 1). There were no or limited changes in most COG categories, except for “poorly characterized” and “amino acid transport and metabolism”. For example, no differentially expressed genes were found in the “energy production and conversion” category under sub-inhibitory Ery treatment (Table 2), while a large portion of genes in this category were down-regulated under the treatment of an inhibitory does of Ery (Table 1). In the “cell motility” category, only two genes were up-regulated under the sub-inhibitory Ery treatment, but a number of genes in this category were up-regulated in response to an inhibitory dose of Ery (Table 1). Additionally, no genes in the “translation” category were altered in expression under the sub-inhibitory dose, but multiple genes in this category were up-regulated when treated with an inhibitory dose. These differences suggest that the sub-inhibitory dose of Ery did not significantly affect the fundamental metabolism of C. jejuni. Despite these major differences, there were 14 genes that showed consistent trends of differential expression under both inhibitory and sub-inhibitory treatments (Table 3). Among the 14 genes include a two-component sensor kinase (cj1226c), omp50 (cj1170c), and fliA (cj0061c). Interestingly, several COG categories did not show any appreciable gene expression changes regardless of the doses of Ery exposure. These categories include cell “cycle control, mitosis and meiosis”, “intracellular trafficking and secretion” as well as those involved in transport and metabolism of lipids and nucleic acids (Tables 1 and 2). Together, these findings suggest that Ery exposure invokes transcriptional responses that are more prominent in certain metabolic pathways and are influenced by the doses of the antibiotic.
Several differentially expressed genes were selected for detailed studies by generating insertional mutants in the study. The selection was based on their predicted or known functions (for the PMSR genes and the cj1169c-cj1170c operon) or the magnitude of differential expression (for the cj0423-cj0425 operon). Interestingly, mutation of these selected genes did not affect the susceptibility of C. jejuni to Ery, although their expression was up-regulated in the presence of this antibiotic. This finding suggests that these genes are involved in the response to Ery treatment, but may not contribute directly to macrolide resistance. Alternatively, these genes may contribute to Ery resistance when they are over expressed. This possibility is not examined in this study and remains to be evaluated. Additionally, functional redundancy of genes may compensate for the inactivation of the selected genes, preventing an obvious change in the susceptibility to Ery.
PSMR transporters in other bacteria have been demonstrated to confer resistance to numerous toxic compounds including quaternary ammonium compounds, toxic lipophilic compounds, potentially toxic metabolites and polyamine compounds [21, 28, 29]. Not all PSMR proteins are associated with an antibiotic resistance phenotype , highlighting the diversity in substrate recognition by PSMR transporters. In C. jejuni, the substrates recognized and exported by Cj0309c-Cj0310c and Cj1173-Cj1174 remain unknown. However, their mutants showed reduced survival compared to the wild-type strain at 18.5% O2 (Figure 2A), suggesting that the PSMR proteins may contribute to Campylobacter survival under high-level oxygen tension such as the conditions encountered outside of the host during transmission. However, the chicken experiments demonstrated that the mutant strains were comparable to the wild-type strain in the ability to colonize and spread among birds (Figure 3), suggesting that the Campylobacter PSMR transporters are not essential for in vivo colonization and transmission. One potential caveat of the chicken experiment is the short-term nature of the study and the continuous shedding of fresh Campylobacter (from the seeder birds) that were available for the naïve birds, which may not allow evaluation of the role of the PSMR genes in long-term survival and transmission. This possibility requires further examination in future studies.
cj0425 was identified as up-regulated (>100 fold) by microarray when C. jejuni was treated with an inhibitory dose of Ery (Additional file 1), and qRT-PCR confirmed this change (Table 4). In this study, we provided empirical evidence that cj0423-cj0425 are co-transcribed from the same operon (data not shown). Little is known about the function of this operon. Previously, it was demonstrated that cj0425 (encoding a putative periplasmic protein) was down-regulated under low oxygen conditions and is considered to be involved in oxidative-tolerance phenotype of C. jejuni[30, 31]. However, it is shown in this study that C. jejuni wild-type NCTC 11168 and its Δcj0425 isogenic mutant strain (KO423Q) had comparable level of resistance to the oxidative stress generating compounds tested in this study (result not shown), suggesting that it is not directly involved in oxidative stress resistance.
Omp50 (cj1170c) of C. jejuni was previously characterized to belong to the monomeric group of porins which is typical of the OmpA-like family . Omp50 was also found to be species-specific and present only in C. jejuni and C. lari, but not in C. coli. Previous studies showed that the temperature regulated Omp50 maybe an alternative porin to the major outer membrane protein (MOMP), contributing to decreased membrane permeability while still allowing nutrient uptake [33, 34]. However, a recent study identified Omp50 as an outer-membrane phosphotyrosine kinase that modulates phosphorylation of multiple outer membrane proteins and carbohydrate biosynthesis in C. jejuni. Specifically, Omp50 positively regulates UDP-GlcNAc/Glc 4-epimerase, which is required for N-glycosylation, capsule production and virulence. In this study, it was found that expression of Omp50 and the downstream gene cj1169c was up-regulated in response to both high and low doses of Ery treatment (Tables 3 and 4). This up-regulation could be an adaptive response as increasing expression of surface polysaccharides is expected to reduce cell permeability to Ery, which is a hydrophobic antibiotic. Additionally, it was shown in this study that the Omp50 mutant (KOp50Q) was less tolerant than the wild-type to high levels of oxygen (Figure 2C), showed reduced colonization in chickens, and delayed transmission between seeder birds and non-inoculated birds (Figure 4). These phenotypic changes could be explained by the role of Omp50 in protecting Campylobacter against reactive oxygen species produced by host intestinal epithelium  and against high oxygen tension encountered during fecal-oral transmission. Together, these findings suggest that the cj1169c-cj1170c operon contributes to Campylobacter adaptation in vitro and in animal hosts.
In summary, the findings from this study indicate that Ery treatment of C. jejuni elicits a transcriptomic response that affects a wide range of functional categories. The most notable changes are up-regulation of motility genes and down-regulation of genes involved in energy production and conversion. The transcriptomic response is influenced by the doses of Ery and is prevented by the resistance-conferring mutation in the 23S RNA. Inactivation of several selected genes did not affect the susceptibility of C. jejuni to Ery, but some of the mutant strains showed reduced tolerance to oxygen in vitro and decreased colonization in chickens. Together, these results suggest the adaptive responses may contribute to the survival of C. jejuni under antibiotic stress and facilitate the development of Ery-tolerant/resistant variants.
Strains, media, and growth conditions
Bacterial strains and plasmids used in this study are listed in Table 5. Campylobacter strains were routinely cultured from frozen stocks (−80°C) on Mueller-Hinton (MH) agar or broth at 42°C under microaerobic conditions (85% N2, 10% CO2 and 5% O2). For oxygen-stress experiments, the strains were grown on MH agar under an increased oxygen containing atmosphere (76.5% N2, 5% CO2, and 18.5% O2) at 37°C. E. coli was grown in Luria-Bertani (LB) broth or agar at 37°C. The media was supplemented with chloramphenicol (4 mg/L; ACROS), kanamycin (30 mg/L; Sigma), or tetracycline (5 mg/L; Sigma) when needed.
Growth rate and antibiotic susceptibility test
To assess in vitro growth, C. jejuni strains were inoculated into MH broth to a density of 107 CFU mL-1 and incubated with shaking (160 rpm) at 42°C under microaerobic conditions. Optical density at 600 nm (OD600) was monitored by a spectrophotometer (Bio-Rad smartspec™3000, Hercules, CA) at various time points (2 h, 4 h, 6 h, and 8 h post inoculation).
The minimum inhibitory concentrations (MIC) of Ery and other antimicrobials for NCTC 11168 and its mutant strains were determined by a microtiter broth dilution method as described previously . The antibiotics and compounds were purchased from Sigma (ampicillin, Ery, streptomycin, novobiocin, nalidixic acid, tetracycline, phosphonomycin, cetylpyridinium chloride), Fisher Scientific (crystal violet, erythromycin), ACROS (chloramphenicol), IBI Scientific (ethidium bromide (EB)), Fluka (ciprofloxacin), Ambion (SDS), and Alfa Aesar (spermidine). Results were recorded after 24 h incubation under microaerobic conditions at 42°C. Tests for each compound were repeated three times.
DNA microarray experiments
Wild-type C. jejuni NCTC 11168 (Ery MIC: 0.25 mg/L) and its erythromycin-resistant (EryR) derivative strain JL272 (Ery MIC: 1024 mg/L)  were grown separately for 5 hours in MH to OD600 of approximately 0.2 with shaking (160 rpm) at 42°C under microaerobic condition. Fifteen mL aliquots of NTCT 11168 culture (in triplicates) were treated with either sham (ethanol solvent for Ery), an inhibitory dose of Ery (4 mg/L; 16× MIC), or a sub-inhibitory dose of Ery (0.125 mg/L; 0.5× MIC). All cultures including the sham control were thoroughly mixed and statically incubated under microaerobic conditions for 30 minutes at 42°C. Strain JL272 was treated with 4 mg/L Ery (16× MIC of the wild-type strain) or the sham under the same condition as with NCTC 11168. After 30 minutes treatment, the cultures were immediately mixed with RNAprotect™ (Qiagen, Valencia, CA) to stabilize the total bacterial RNA. Total RNA was extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer’s protocol and treated with TURBO DNase (Invitrogen, Carlsbad, CA). RNA quantity was determined by OD260 reading using a NanoDrop spectrometer (Thermo Scientific, Wilmington, DE), and the purity was assessed by denaturing agarose gel electrophoresis. RNA samples confirmed free of DNA contamination by PCR of 16S rRNA gene, were stored at −80°C until use. Three independent RNA isolations (biological replicates) were performed for microarray experiments.
C. jejuni microarray slides (version 3 for NCTC 11168 inhibitory treatment, version 4 for NCTC 11168 sub-inhibitory treatment, and version 1 for JL272 Ery treament) were designed and provided by the Pathogen Functional Genomics Resource Center (PFGRC) at the J. Craig Venter Institute (JCVI, Rockville, MD). cDNA synthesis, labeling of cDNA and hybridization of labeled cDNA to the microarray slides were performed according to the JCVI’s protocol (http://pfgrc.jcvi.org/index.php/microarray/protocols.html). For each pair of treated and untreated samples, hybridizations were performed with RNA samples prepared from three independent experiments, with the cDNA alternately labeled with Cy3 and Cy5 for the pair in each slide.
Slides were dried using a microarray high speed centrifuge (Arrayit, Sunnyvale, CA) and immediately scanned at a wavelength of 550 nm for Cy3 and 650 nm for Cy5 using a General Scanning ScanArray 5000 (PerkinElmer, Boston, MA) at 10 μm resolution. Slide information and annotation files were obtained from the JCVI website (http://pfgrc.jcvi.org/index.php/microarray/available_microarrays/.html). The fluorescence intensities were collected and converted to digital signal by ImaGene software (BioDiscovery, EI Segundo, CA). The fluorescence intensity values were logarithm-transformed, median background corrected, and LOWESS normalized. The normalized gene expression data were analyzed using moderated-t test implemented in the R package, LIMMA . In this study, a p-value < 0.01, relative fold-change ≥ 2 were chosen as the cutoff for identification of genes with a significant differential expression between the treatment and control samples. The microarray data have been deposited in the NCBI Gene Expression Ommibus (http://www.ncbi.nlm.nih.gov/gds/) and the accession number is GSE43026.
Quantitative real-time RT-PCR
A quantitative real-time RT-PCR (qRT-PCR) was used to confirm the expression levels of representative genes that were identified as differentially expressed by the microarray. Briefly, reactions were performed using the iQTM SYBRR Green Super Mix (Bio-Rad, Hercules, CA) and MyiQTM instrument (Bio-Rad). Primers were designed by Primer 3 software (http://frodo.wi.mit.edu/) and are listed in Table 6. The 16S rRNA transcript was used to normalize target gene expression. Amplification efficiency and relative transcript abundance (R) were calculated as previously described . R values were log2 transformed to meet assumptions of normality and variance; statistical significance was determined by the two tailed Student’s t-test under the null hypothesis of R = 0.
Construction and complementation of insertional mutants
Isogenic C. jejuni NCTC 11168 mutant strains with a disrupted copy of cj0309c-cj0310c, cj0423-cj0425, cj1169c-cj1170c, or cj1173-cj1174 genes were constructed by insertional mutagenesis with antibiotic resistance cassettes. The strategies are shown in Figure 1. Primers used in the construction and complementation of mutants are listed in Table 6. The chloramphenicol (cat) and kanamycin (aphA-3) resistance cassettes were PCR amplified using Ex-Taq (Takara Bio Inc.) from plasmids pUOA18 and pMW10 with cat and aphA3 primers, respectively, as described in a previous study . PCR products were digested with the appropriate restriction enzymes (Table 6, Figure 1). The PCR products and a resistance cassette were ligated by T4 DNA ligase (Promega, Madison, WI), cloned into suicide vector pUC19 (Invitrogen, Carlsbad, CA), and transformed into competent E. coli DH5α (Invitrogen). Recombinant clones with the intended mutation were confirmed by PCR. Plasmids were extracted from DH5α and used to transform wild-type NCTC 11168 by the standard biphasic method for natural transformation . Transformants were colony purified on MH plates with supplemented antibiotics. Single colonies were selected and confirmed by PCR. Mutations were complemented by inserting the entire set of the wild-type copy of genes between the structural genes of the ribosomal gene cluster in the corresponding mutant strains as described previously [37, 40]. PCR amplification and sequencing were performed on positive clones to confirm no mutations occurred in the cloned sequences. All strains were stored at −80°C for later use.
Oxidative stress tests
To determine if the mutated genes affected the susceptibility of C. jejuni to oxidative stress, wild-type NCTC 11168 and mutant strains (KO39Q、KO73Q、KO425Q、KOp50Q and DKO01Q) were compared using two oxidative stress tests. In the first test, inhibition of hydrogen peroxide (H2O2), cumene hydroperoxide and menadione on bacterial growth at 24 and 48 h on MH plate incubated microaerobically at 42°C were measured by a disk diffusion method as described previously , with the following modification: The concentrations of H2O2, cumene hydroperoxide and menadione used were 1.5%, 2% and 45 mM, respectively. In the second test, oxygen tolerance of wild-type and mutant strains was determined by measuring the viability/growth after incubation at different oxygen levels (5% O2 or 18.5% O2) as described previously  with modifications. Briefly, serial dilutions of overnight cultures were spotted (5 μl) onto MH agar plates and incubated at 37°C in incubators containing either 5% O2, 10% CO2, 85% N2 or 18.5% O2, 5% CO2, 76.5% N2 (Forma Scientific, model 3130). Growth was examined after 48 h of incubation. Experiments were repeated three times independently.
Colonization and transmission experiments in chickens
To investigate if cj0309c-cj0310c and cj1173-cj1174, which encode putative multidrug efflux systems, affect Campylobacter adaptation in chickens, 3-day-old commercial broiler chickens (Ross & Ross) were randomly assigned to 4 groups (15 bird/group) and inoculated with NCTC 11168 (group 1), KO39Q (Δcj0309c-cj0310c, group 2), KO73Q (Δcj1173-cj1174, group 3), and DKO01Q (Δcj0309c-cj0310 and Δcj1173-cj1174, group 4), respectively. Each bird received approximately 1x107 CFU of respective strain via oral gavage. The birds were free of Campylobacter colonization as determined by culturing of cloacal swabs prior to inoculation. Cecal contents were collected from each bird at necropsy on 5, 10, and 15 DAI. The total number of Campylobacter in each sample was determined by serial dilution and viable counts on agar plates containing Campylobacter-specific growth and selective supplements (Oxoid, United Kingdom). The samples from groups 2, 3, and 4 were also plated on Campylobacter-selective agar plates containing kanamycin or/and chloramphenicol as described earlier to confirm the mutations. Campylobacter counts were determined after 48 h incubation microaerobically at 42°C, and expressed as CFU/g feces for each bird at each sampling point.
In addition to the colonization experiment described above, co-mingling experiments were carried out to determine the transmissibility of mutant strains from Campylobacter-inoculated seeder birds to naive (non-inoculated) birds. The strains used in this study included the wild type strain NCTC 11168 (group 1), DKO01Q (Δcj0309c-cj0310c and Δcj1173-cj1174,group 2), KOp50Q (Δcj1169c-cj1170c,group 3), and Comp50Q (complemented KOp50Q strain, group 4). One-day-old commercial broiler chickens (Ross & Ross) were randomly assigned to four groups (n = 12 for groups inoculated with KOp50Q or DKO01Q; n = 13 for the groups with NCTC 11168 or Comp50Q), which were segregated by cardboard pens in separate rooms. Three birds (marked with a permanent marker) in each group were randomly chosen and inoculated with a dose of 107 CFU of respective strain via oral gavage at day 3 of age. After inoculation, the inoculated birds were immediately returned to the respective groups and allowed to comingle with non-inoculated birds. Cloacal swabs were collected from each bird at 3, 6, and 9 DAI for determining the positivity (with Campylobacter) of the birds. Additionally, the birds were necropsied at 9 and 12 DAI (n = 6 or 7 for each time point) and the cecal contents were collected for measuring the level of colonization. It should be pointed out that in terms of time frame the DAI were the same as days after initiation of comingling as the co-mingling occurred immediately after inoculation of the seeder birds. Cloacal swabs were streaked on the selective agar media to determine Campylobacter presence/absence. Cecal contents were serially diluted and tested to quantify Campylobacter colonies as described above.
The detection limit of the culture method used for the chicken experiments was 100 CFU/g of feces. Cecal contents contained less than 100 CFU/g Campylobacter colonies were considered negative and assigned a value of 0 for the purpose of statistical analysis. Significant differences (p < 0.05) in the colonization levels between groups at each sampling time point were determined using Student’s t test, Welch's t test to allow for non-constant variation across treatment groups, and the Wilcoxon rank-sum test to allow for non-normality .
All animals used in this study were handled in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal use protocol was approved by the Institutional Animal Care and Use Committee of Iowa State University (A3236-01). All efforts were made to minimize suffering of animals.
We thank the Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute for generously providing the microarray slides used in this study. Strain JL272 used in this study was kindly supplied by Dr. Jun Lin from the University of Tennessee. This work was supported by funds from National Institute of Health (Grant no: RO1DK063008).
- Jorgensen F, Ellis-Iversen J, Rushton S, Bull SA, Harris SA, Bryan SJ, Gonzalez A, Humphrey TJ: Influence of season and geography on Campylobacter jejuni and C. coli subtypes in housed broiler flocks reared in Great Britain. Appl Environ Microbiol. 2011, 77 (11): 3741-3748. 10.1128/AEM.02444-10.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen J, Sun XT, Zeng Z, Yu YY: Campylobacter enteritis in adult patients with acute diarrhea from, 2005 to 2009 in Beijing, China. Chin Med J (Engl). 2011, 124 (10): 1508-1512.Google Scholar
- Koga M, Gilbert M, Takahashi M, Li J, Koike S, Hirata K, Yuki N: Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis. 2006, 193 (4): 547-555. 10.1086/499969.PubMedView ArticleGoogle Scholar
- Skirrow MBM: Clinical aspects of Campylobacter infection. 2000, Washington, DC: ASM Press, 2Google Scholar
- Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I: Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001, 7 (1): 24-34. 10.3201/eid0701.010104.PubMedPubMed CentralView ArticleGoogle Scholar
- Gibreel A, Taylor DE: Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. 2006, 58 (2): 243-255. 10.1093/jac/dkl210.PubMedView ArticleGoogle Scholar
- Poehlsgaard J, Douthwaite S: The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol. 2005, 3 (11): 870-881. 10.1038/nrmicro1265.PubMedView ArticleGoogle Scholar
- Brisson-Noel A, Trieu-Cuot P, Courvalin P: Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother. 1988, 22 (Suppl B): 13-23.PubMedGoogle Scholar
- Anadon A, Reeve-johnson L: Macrolide antibiotics, drug interactions and microsomal enzymes: implications for veterinary medicine. Res Vet Sci. 1999, 66 (3): 197-203. 10.1053/rvsc.1998.0244.PubMedView ArticleGoogle Scholar
- Hao H, Dai M, Wang Y, Peng D, Liu Z, Yuan Z: 23S rRNA mutation A2074C conferring high-level macrolide resistance and fitness cost in Campylobacter jejuni. Microb Drug Resist. 2009, 15 (4): 239-244. 10.1089/mdr.2009.0008.PubMedView ArticleGoogle Scholar
- Guo B, Wang Y, Shi F, Barton YW, Plummer P, Reynolds DL, Nettleton D, Grinnage-Pulley T, Lin J, Zhang Q: CmeR functions as a pleiotropic regulator and is required for optimal colonization of Campylobacter jejuni in vivo. J Bacteriol. 2008, 190 (6): 1879-1890. 10.1128/JB.01796-07.PubMedPubMed CentralView ArticleGoogle Scholar
- Ng WL, Kazmierczak KM, Robertson GT, Gilmour R, Winkler ME: Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. J Bacteriol. 2003, 185 (1): 359-370. 10.1128/JB.185.1.359-370.2003.PubMedPubMed CentralView ArticleGoogle Scholar
- VanBogelen RA, Neidhardt FC: Ribosomes as sensors of heat and cold shock in Escherichia coli. Proc Natl Acad Sci USA. 1990, 87 (15): 5589-5593. 10.1073/pnas.87.15.5589.PubMedPubMed CentralView ArticleGoogle Scholar
- Evers S, Di Padova K, Meyer M, Langen H, Fountoulakis M, Keck W, Gray CP: Mechanism-related changes in the gene transcription and protein synthesis patterns of Haemophilus influenzae after treatment with transcriptional and translational inhibitors. Proteomics. 2001, 1 (4): 522-544. 10.1002/1615-9861(200104)1:4<522::AID-PROT522>3.0.CO;2-#.PubMedView ArticleGoogle Scholar
- Qiu J, Zhou D, Qin L, Han Y, Wang X, Du Z, Song Y, Yang R: Microarray expression profiling of Yersinia pestis in response to chloramphenicol. FEMS Microbiol Lett. 2006, 263 (1): 26-31. 10.1111/j.1574-6968.2006.00394.x.PubMedView ArticleGoogle Scholar
- Reiss S, Pane-Farre J, Fuchs S, Francois P, Liebeke M, Schrenzel J, Lindequist U, Lalk M, Wolz C, Hecker M, et al: Global analysis of the Staphylococcus aureus response to mupirocin. Antimicrob Agents Chemother. 2012, 56 (2): 787-804. 10.1128/AAC.05363-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Kaldalu N, Mei R, Lewis K: Killing by ampicillin and ofloxacin induces overlapping changes in Escherichia coli transcription profile. Antimicrob Agents Chemother. 2004, 48 (3): 890-896. 10.1128/AAC.48.3.890-896.2004.PubMedPubMed CentralView ArticleGoogle Scholar
- Han J, Sahin O, Barton YW, Zhang Q: Key role of Mfd in the development of fluoroquinolone resistance in Campylobacter jejuni. PLoS Pathog. 2008, 4 (6): e1000083-10.1371/journal.ppat.1000083.PubMedPubMed CentralView ArticleGoogle Scholar
- Tareen AM, Dasti JI, Zautner AE, Gross U, Lugert R: Campylobacter jejuni proteins Cj0952c and Cj0951c affect chemotactic behaviour towards formic acid and are important for invasion of host cells. Microbiology. 2010, 156 (Pt 10): 3123-3135.PubMedView ArticleGoogle Scholar
- Lin J, Yan M, Sahin O, Pereira S, Chang YJ, Zhang Q: Effect of macrolide usage on emergence of erythromycin-resistant Campylobacter isolates in chickens. Antimicrob Agents Chemother. 2007, 51 (5): 1678-1686. 10.1128/AAC.01411-06.PubMedPubMed CentralView ArticleGoogle Scholar
- Bay DC, Rommens KL, Turner RJ: Small multidrug resistance proteins: a multidrug transporter family that continues to grow. Biochim Biophys Acta. 2008, 1778 (9): 1814-1838. 10.1016/j.bbamem.2007.08.015.PubMedView ArticleGoogle Scholar
- Bay DC, Turner RJ: Diversity and evolution of the small multidrug resistance protein family. BMC Evol Biol. 2009, 9: 140-10.1186/1471-2148-9-140.PubMedPubMed CentralView ArticleGoogle Scholar
- Bolla JM, De E, Dorez A, Pages JM: Purification, characterization and sequence analysis of Omp50, a new porin isolated from Campylobacter jejuni. Biochem J. 2000, 352 (Pt 3): 637-643.PubMedPubMed CentralView ArticleGoogle Scholar
- Corcionivoschi N, Alvarez LA, Sharp TH, Strengert M, Alemka A, Mantell J, Verkade P, Knaus UG, Bourke B: Mucosal reactive oxygen species decrease virulence by disrupting Campylobacter jejuni phosphotyrosine signaling. Cell Host Microbe. 2012, 12 (1): 47-59. 10.1016/j.chom.2012.05.018.PubMedPubMed CentralView ArticleGoogle Scholar
- Jagannathan A, Constantinidou C, Penn CW: Roles of rpoN, fliA, and flgR in expression of flagella in Campylobacter jejuni. J Bacteriol. 2001, 183 (9): 2937-2942. 10.1128/JB.183.9.2937-2942.2001.PubMedPubMed CentralView ArticleGoogle Scholar
- Yokoyama T, Paek S, Ewing CP, Guerry P, Yeo HJ: Structure of a sigma28-regulated nonflagellar virulence protein from Campylobacter jejuni. J Mol Biol. 2008, 384 (2): 364-376. 10.1016/j.jmb.2008.09.036.PubMedPubMed CentralView ArticleGoogle Scholar
- Allen KJ, Griffiths MW: Effect of environmental and chemotactic stimuli on the activity of the Campylobacter jejuni flaA sigma(28) promoter. FEMS Microbiol Lett. 2001, 205 (1): 43-48.PubMedGoogle Scholar
- Ganas P, Mihasan M, Igloi GL, Brandsch R: A two-component small multidrug resistance pump functions as a metabolic valve during nicotine catabolism by Arthrobacter nicotinovorans. Microbiology. 2007, 153 (Pt 5): 1546-1555.PubMedView ArticleGoogle Scholar
- Higashi K, Ishigure H, Demizu R, Uemura T, Nishino K, Yamaguchi A, Kashiwagi K, Igarashi K: Identification of a spermidine excretion protein complex (MdtJI) in Escherichia coli. J Bacteriol. 2008, 190 (3): 872-878. 10.1128/JB.01505-07.PubMedPubMed CentralView ArticleGoogle Scholar
- Kaakoush NO, Miller WG, De Reuse H, Mendz GL: Oxygen requirement and tolerance of Campylobacter jejuni. Res Microbiol. 2007, 158 (8–9): 644-650.PubMedView ArticleGoogle Scholar
- Woodall CA, Jones MA, Barrow PA, Hinds J, Marsden GL, Kelly DJ, Dorrell N, Wren BW, Maskell DJ: Campylobacter jejuni gene expression in the chick cecum: evidence for adaptation to a low-oxygen environment. Infect Immun. 2005, 73 (8): 5278-5285. 10.1128/IAI.73.8.5278-5285.2005.PubMedPubMed CentralView ArticleGoogle Scholar
- Dedieu L, Pages JM, Bolla JM: Use of the omp50 gene for identification of Campylobacter species by PCR. J Clin Microbiol. 2004, 42 (5): 2301-2305. 10.1128/JCM.42.5.2301-2305.2004.PubMedPubMed CentralView ArticleGoogle Scholar
- Dedieu L, Pages JM, Bolla JM: Environmental regulation of Campylobacter jejuni major outer membrane protein porin expression in Escherichia coli monitored by using green fluorescent protein. Appl Environ Microbiol. 2002, 68 (9): 4209-4215. 10.1128/AEM.68.9.4209-4215.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Dedieu L, Pages JM, Bolla JM: The omp50 gene is transcriptionally controlled by a temperature-dependent mechanism conserved among thermophilic Campylobacter species. Res Microbiol. 2008, 159 (4): 270-278. 10.1016/j.resmic.2008.03.002.PubMedView ArticleGoogle Scholar
- Lin J, Michel LO, Zhang Q: CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother. 2002, 46 (7): 2124-2131. 10.1128/AAC.46.7.2124-2131.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Luangtongkum T, Shen Z, Seng VW, Sahin O, Jeon B, Liu P, Zhang Q: Impaired fitness and transmission of macrolide-resistant Campylobacter jejuni in its natural host. Antimicrob Agents Chemother. 2012, 56 (3): 1300-1308. 10.1128/AAC.05516-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Muraoka WT, Zhang Q: Phenotypic and genotypic evidence for L-fucose utilization by Campylobacter jejuni. J Bacteriol. 2011, 193 (5): 1065-1075. 10.1128/JB.01252-10.PubMedPubMed CentralView ArticleGoogle Scholar
- Guo B, Lin J, Reynolds DL, Zhang Q: Contribution of the multidrug efflux transporter CmeABC to antibiotic resistance in different Campylobacter species. Foodborne Pathog Dis. 2010, 7 (1): 77-83. 10.1089/fpd.2009.0354.PubMedPubMed CentralView ArticleGoogle Scholar
- Wang Y, Taylor DE: Natural transformation in Campylobacter species. J Bacteriol. 1990, 172 (2): 949-955.PubMedPubMed CentralGoogle Scholar
- Karlyshev AV, Wren BW: Development and application of an insertional system for gene delivery and expression in Campylobacter jejuni. Appl Environ Microbiol. 2005, 71 (7): 4004-4013. 10.1128/AEM.71.7.4004-4013.2005.PubMedPubMed CentralView ArticleGoogle Scholar
- Flint A, Sun YQ, Stintzi A: Cj1386 is an ankyrin-containing protein involved in heme trafficking to catalase in Campylobacter jejuni. J Bacteriol. 2012, 194 (2): 334-345. 10.1128/JB.05740-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Tal N, Schuldiner S: A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc Natl Acad Sci USA. 2009, 106 (22): 9051-9056. 10.1073/pnas.0902400106.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.